KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Current Deferred Revenue (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Current Deferred Revenue for 6 consecutive years, with $37.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue fell 39.12% year-over-year to $37.6 million, compared with a TTM value of $37.6 million through Dec 2025, down 39.12%, and an annual FY2025 reading of $37.6 million, down 39.12% over the prior year.
  • Current Deferred Revenue was $37.6 million for Q4 2025 at Recursion Pharmaceuticals, down from $47.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $73.1 million in Q2 2023 and bottomed at $2.5 million in Q1 2022.
  • Average Current Deferred Revenue over 5 years is $39.7 million, with a median of $39.7 million recorded in 2025.
  • The sharpest move saw Current Deferred Revenue tumbled 75.0% in 2022, then surged 2210.44% in 2023.
  • Year by year, Current Deferred Revenue stood at $10.0 million in 2021, then surged by 467.26% to $56.7 million in 2022, then plummeted by 35.79% to $36.4 million in 2023, then surged by 69.57% to $61.8 million in 2024, then crashed by 39.12% to $37.6 million in 2025.
  • Business Quant data shows Current Deferred Revenue for RXRX at $37.6 million in Q4 2025, $47.4 million in Q3 2025, and $39.7 million in Q2 2025.